Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Moon DG et al. | Platelet modulation of neutrophil superoxide anion production. | 1990 | Thromb. Haemost. | pmid:2160133 |
Vargaftig BB et al. | Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. | 1982 | Thromb. Haemost. | pmid:7135345 |
Wal F et al. | PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin. | 1985 | Thromb. Haemost. | pmid:3992525 |
Selak MA | Neutrophil elastase potentiates cathepsin G-induced platelet activation. | 1992 | Thromb. Haemost. | pmid:1333649 |
Smith SV and Brinkhous KM | Inventory of exogenous platelet-aggregating agent derived from venoms. | 1991 | Thromb. Haemost. | pmid:1771620 |
Xavier RG et al. | Enhanced platelet aggregation and activation under conditions of hypothermia. | 2007 | Thromb. Haemost. | pmid:18064324 |
Hermán F et al. | Decreased sensitivity of platelets to platelet-activating factor in migraine patients during the headache-free interval. | 1989 | Thromb. Haemost. | pmid:2814933 |
Handley DA et al. | Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. | 1985 | Thromb. Haemost. | pmid:4089809 |
den Dekker E et al. | Biogenesis of G-protein mediated calcium signaling in human megakaryocytes. | 2001 | Thromb. Haemost. | pmid:11686331 |
Ward JR et al. | Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. | 2005 | Thromb. Haemost. | pmid:16270639 |
Handley DA et al. | Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. | 1986 | Thromb. Haemost. | pmid:3775689 |
Ou MC et al. | Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. | 1994 | Thromb. Res. | pmid:8191415 |
Le Blanc K et al. | Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. | 1998 | Thromb. Res. | pmid:9772010 |
Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
Powling MJ and Hardisty RM | Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. | 1986 | Thromb. Res. | pmid:3787566 |
Siffert W et al. | Inhibition of platelet aggregation by amiloride. | 1986 | Thromb. Res. | pmid:3787567 |
Alam I et al. | Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. | 1983 | Thromb. Res. | pmid:6407140 |
Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
Bush LR and Smith SG | Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. | 1986 | Thromb. Res. | pmid:2948294 |
Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
Slattery CW and Beaumont DO | Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. | 1989 | Thromb. Res. | pmid:2554526 |
Belch JJ et al. | Whole blood white cell aggregation: a novel technique. | 1987 | Thromb. Res. | pmid:2448894 |
Ostermann G et al. | Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. | 1983 | Thromb. Res. | pmid:6408754 |
Nguyên P et al. | Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. | 1995 | Thromb. Res. | pmid:7778064 |
Vargaftig BB et al. | Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. | 1982 | Thromb. Res. | pmid:7164036 |
Namm DH and High JA | Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. | 1980 | Thromb. Res. | pmid:7209881 |
Hanss M and Dechavanne M | 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. | 1988 | Thromb. Res. | pmid:3126559 |
Okamoto M et al. | Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. | 1986 | Thromb. Res. | pmid:3754990 |
Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
Namm DH et al. | Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. | 1982 | Thromb. Res. | pmid:7071810 |
Violi F et al. | Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. | 1989 | Thromb. Res. | pmid:2506658 |
Shukla SD et al. | Hypersensitivity of diabetic human platelets to platelet activating factor. | 1992 | Thromb. Res. | pmid:1329254 |
Tsien WH et al. | Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. | 1982 | Thromb. Res. | pmid:7164038 |
Kurose I et al. | Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. | 1991 | Thromb. Res. | pmid:1650966 |
Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
Valone FH | Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. | 1987 | Thromb. Res. | pmid:3590086 |
Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. | 1987 | Thromb. Res. | pmid:3590110 |
Brown JE and Thuy LP | The binding of bovine platelet aggregating factor to human platelets. | 1981 Apr 1-15 | Thromb. Res. | pmid:7292446 |
Kloprogge E et al. | Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. | 1983 | Thromb. Res. | pmid:6222507 |
Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
Wade PJ et al. | Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. | 1986 | Thromb. Res. | pmid:3961730 |
Karlsson H et al. | Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. | 1998 | Thromb. Res. | pmid:9694244 |
Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
Cox CP and Wood KL | Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. | 1987 | Thromb. Res. | pmid:3629553 |
Catalán RE et al. | Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. | 1994 | Thromb. Res. | pmid:7974386 |
Ostermann G et al. | Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. | 1987 | Thromb. Res. | pmid:3629555 |
Davis RB and Johnson MF | Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. | 1986 | Thromb. Res. | pmid:3544327 |
Nishizawa EE and Della-Coletta AA | The formation of a thrombin-like material (TLM) following stimulation of leukocytes. | 1984 | Thromb. Res. | pmid:6484896 |
Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
Stahl GL et al. | Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. | 1989 | Thromb. Res. | pmid:2718150 |
Valone FH | Platelet-activating factor binding and metabolism during human platelet aggregation. | 1988 | Thromb. Res. | pmid:3400077 |
Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
Sloan IG and Firkin BG | Impaired fibrinolysis in patients with thrombotic or haemostatic defects. | 1989 | Thromb. Res. | pmid:2814943 |
Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
Griffin KJ and Levy JV | The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). | 1988 | Thromb. Res. | pmid:3187959 |
Petty AC and Scrutton MC | Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? | 1989 | Thromb. Res. | pmid:2749609 |
Lalau Keraly C et al. | Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. | 1984 | Thromb. Res. | pmid:6740569 |
Beaumont DO et al. | Measuring platelet function with platelet shape change, an early event in aggregation. | 1989 | Thromb. Res. | pmid:2646752 |
Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
Violi F et al. | Human platelet aggregation by PAF and thromboxane production. | 1987 | Thromb. Res. | pmid:3424290 |
Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
Seth P et al. | Effect of platelet activating factor antagonists in different models of thrombosis. | 1994 | Thromb. Res. | pmid:7900097 |
Bernat A and Herbert JM | Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. | 1994 | Thromb. Res. | pmid:8073411 |
Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
Cox CP | Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. | 1986 | Thromb. Res. | pmid:2421432 |
Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
Croft KD and Beilin LJ | Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. | 1993 | Thromb. Res. | pmid:8385810 |
Vrzheshch PV et al. | Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. | 1992 | Thromb. Res. | pmid:1523610 |
Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
Chlopicki S et al. | Obligatory role of lipid mediators in platelet-neutrophil adhesion. | 2003 | Thromb. Res. | pmid:14592550 |
Valone FH and Johnson B | Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. | 1985 | Thromb. Res. | pmid:4082115 |
Kohayakawa M and Inoue K | Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. | 1986 | Thromb. Res. | pmid:3083530 |
Battistini B et al. | Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. | 1990 | Thromb. Res. | pmid:2278035 |
Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
Hadváry P and Baumgartner HR | Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. | 1983 | Thromb. Res. | pmid:6868019 |
Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
Tan EL and Snyder F | Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. | 1985 | Thromb. Res. | pmid:4024051 |
Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
Bussolino F et al. | Intravascular release of platelet activating factor in children with sepsis. | 1987 | Thromb. Res. | pmid:3441909 |
Küster LJ and Frölich JC | PAF-induced platelet aggregation and TXB2 formation. | 1989 | Thromb. Res. | pmid:2922704 |
Ostermann G et al. | Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. | 1986 | Thromb. Res. | pmid:3764811 |
Ishii H et al. | A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. | 1982 | Thromb. Res. | pmid:6897588 |
Ostermann G et al. | The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. | 1988 | Thromb. Res. | pmid:3232123 |
Avdonin PV et al. | Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. | 1988 | Thromb. Res. | pmid:3232128 |
Neiman J et al. | Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. | 1989 | Thromb. Res. | pmid:2617478 |
Pfliegler G et al. | Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. | 1993 | Thromb. Res. | pmid:8503122 |
Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
Avdonin PV et al. | Evidence for the receptor-operated calcium channels in human platelet plasma membrane. | 1987 | Thromb. Res. | pmid:2438805 |
Lukaszyk A et al. | Does acute experimental pancreatitis affect blood platelet function? | 1989 | Thromb. Res. | pmid:2524119 |
Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
McGowan EB and Detwiler TC | Characterization of the thrombin-induced desensitization of platelet activation by thrombin. | 1983 | Thromb. Res. | pmid:6356458 |
Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
Kinlough-Rathbone RL et al. | Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. | 1999 | Thromb. Res. | pmid:10527409 |
Csáki C et al. | Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. | 1992 | Thromb. Res. | pmid:1412179 |
May JA et al. | Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. | 1997 | Thromb. Res. | pmid:9361371 |
Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |